REG - GSK PLC - Director/PDMR Shareholding

GSKAnnouncement

Mon 15:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260105:nRSE6963Na&default-theme=true

RNS Number : 6963N  GSK PLC  05 January 2026

GSK plc (the 'Company')

Transaction notification

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     David Redfern
 b)  Position/status                          President, Corporate Development
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Acquisition of Ordinary Shares following the exercise of options granted on 28
                                              November 2022 at the option price of £11.39 per Ordinary Share under the
                                              Company's Share Save Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £11.39                790

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-01-02
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

 1.  Details of PDMR/person closely associated with them ('PCA')
 a)  Name                                     Victoria Whyte
 b)  Position/status                          SVP & Company Secretary
 c)  Initial notification/                    Initial notification

     amendment
 2.  Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                     GSK plc
 b)  LEI                                      5493000HZTVUYLO1D793
 3.  Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transaction(s) has been conducted
 a)  Description of the financial instrument  Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

                                              ISIN: GB00BN7SWP63

 b)  Nature of the transaction                Acquisition of Ordinary Shares following the exercise of options granted on 28
                                              November 2022 at the option price of £11.39 per Ordinary Share under the
                                              Company's Share Save Plan
 c)  Price(s) and volume(s)                                         Price(s)              Volume(s)
                                                                    £11.39                790

 d)  Aggregated information                   N/A (single transaction)

     Aggregated volume Price
 e)  Date of the transaction                  2026-01-02
 f)  Place of the transaction                 London Stock Exchange (XLON)

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at www.gsk.com
(http://www.gsk.com/) .

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHSSLFLIEMSELF



            Copyright 2019 Regulatory News Service, all rights reserved